We will contact you shortly. In the meantime, check out our social media and latest publications

  • The latest from Median

    Median Technologies has been selected as a preferred clinical trial imaging services provider for another leading global pharmaceutical company.
    Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”) today reported its 2023 consolidated annual financial results, as of December 31, 2023, and provided financial information (unaudited) for the first quarter of 2024, as of March 31, 2024.


    Sept 7-11, 2024

    WCLC 2024

    Join us at the World Conference on Lung Cancer (WCLC) in San Diego, CA, from September 7-11, 2024. Visit us at Booth #2601 to discover the latest advancements in eyonisLCS™: